Author

A. Zehir

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Approach:statistical model· 1 Research Focus:trajectory inference· 1

Frequent Co-Authors

C. Famulare· 2 shared R. L. Levine· 2 shared A. D. Goldberg· 1 shared A. D. Viny· 1 shared A. H. Shih· 1 shared A. M. Intlekofer· 1 shared A. Ooi· 1 shared A. Tosolini· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Famulare

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single cell mutational profiling delineates clonal trajectories in myeloid malignancies

L. A. Miles, R. L. Bowman, T. R. Merlinsky, I. S. Csete, A. Ooi, R. Durruthy-Durruthy, M. Bowman, C. Famulare, M. A. Patel, P. Mendez, C. Ainali, M. Manivannan, S. Sahu, A. D. Goldberg, K. Bolton, , R. L. Levine

This study uses single-cell mutational profiling to analyze clonal trajectories in myeloid malignancies, revealing patterns of mutation acquisition and clonal complexity.

bioRxiv · Feb 7, 2020 · PreprintCancer Biology

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

J. J. Harding, M. A. Lowery, A. H. Shih, J. M. Schvartzman, S. Hou, C. Famulare, M. Patel, M. Roshal, R. K. G. Do, A. Zehir, D. You, S. D. Selcuklu, A. Viale, M. S. Tallman, D. M. Hyman, , A. M. Intlekofer

The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.

bioRxiv · Aug 1, 2018Cancer Biology